Compare IOSP & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOSP | AMLX |
|---|---|---|
| Founded | 1938 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 1998 | 2021 |
| Metric | IOSP | AMLX |
|---|---|---|
| Price | $80.09 | $13.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $93.00 | $21.56 |
| AVG Volume (30 Days) | 152.0K | ★ 1.0M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | ★ 228.87 | 65.46 |
| EPS | ★ 1.22 | N/A |
| Revenue | ★ $1,778,000,000.00 | $380,786,000.00 |
| Revenue This Year | $5.96 | N/A |
| Revenue Next Year | $6.10 | N/A |
| P/E Ratio | $65.18 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $65.51 | $4.64 |
| 52 Week High | $92.14 | $18.61 |
| Indicator | IOSP | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 63.12 | 34.52 |
| Support Level | $78.38 | $13.57 |
| Resistance Level | $82.53 | $15.37 |
| Average True Range (ATR) | 1.97 | 0.85 |
| MACD | 0.29 | -0.33 |
| Stochastic Oscillator | 72.52 | 0.25 |
Innospec Inc manufactures and sells a variety of chemicals and fuel additives. The firm organizes itself into three segments based on product type. The Performance Chemicals segment that derives maximum revenue, provides technology-based solutions for its customers' processes or products in personal care, home care, agrochemical, construction, mining and other industrial markets. The Fuel Specialties segment develops, manufactures, blends, markets and supplies a range of specialty chemical products used as additives in diesel, jet, marine, fuel oil and other fuels. The Oilfield Services segment develops and markets chemical solutions for drilling, completion, production, DRA and oil and gas applications.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.